Pilot Surveillance of Babesia,Borrelia burgdorferi,and Anaplasma phagocytophilum Among Chinese Blood Donors—Xinjiang,Inner Mongolia,and Heilongjiang PLADs,China,2022–2023  

作　　者：Huimin Ji Le Chang Ying Yan Huizhen Sun Lunan Wang 

机构地区：[1]National Center for Clinical Laboratories,Institute of Geriatric Medicine,Chinese Academy of Medical Sciences,Beijing Hospital/National Center of Gerontology,Beijing,China [2]Graduate School,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing,China

出　　处：《China CDC weekly》2024年第46期1206-1210,I0003,共6页中国疾病预防控制中心周报（英文）

基　　金：Supported by the National High Level Hospital Clinical Research Funding(BJ-2022-182);CAMS Innovation Fund for Medical Sciences(CIFMS)(2021-I2M-1-060).

摘　　要：What is already known about this topic?Recently,tick-borne pathogens transmitted through blood transfusions have posed new risks to blood safety.What is added by this report?We developed a quality control system for nucleic acid testing(NAT)for Babesia,Borrelia burgdorferi,and Anaplasma phagocytophilum,evaluated five Triplex-NAT kits,and conducted external quality assessments of blood centers.This study screened 92,700 blood donors from Heilongjiang,Inner Mongolia,and Xinjiang provincial-level administrative divisions during 2022–2023.A donor in Hegang,Heilongjiang,tested positive for Borrelia burgdorferi,marking the first detection of this infection in Chinese blood donors.What are the implications for public health practice?Quality control of NAT is vital for managing tickborne pathogen outbreaks.To ensure blood transfusion safety,screening should be strengthened in high-risk areas outside national borders.

关 键 词：Blood STRENGTHENED OUTSIDE 

分 类 号：R513[医药卫生—内科学]